It was demonstrated that radiotherapy can enhance the effect of immunotherapeutic drugs by upregulating PD-L1 expression in the tumor microenvironment, while immune drugs can increase radiosensitivity in ESCC patients and facilitate the effective control of local lesions and distant micrometastases [30, 31]. This evidence concerns the gene CD274 and neoplasm.